Inceptor Bio, a US-based biotechnology company advancing cell therapies for difficult-to-treat cancers, announced on Monday that it has named Dr Matthias Schroff as its new CEO.

The new CEO is also joining the board of directors. He succeeds Shailesh Maingi, who will remain as executive chairman.

Dr Schroff has extensive biopharmaceutical leadership experience. He has served as chief executive officer of Exicure, chief executive officer of Vaximm AG and held several positions on management levels at Mologen, ultimately rising to chief executive officer.